Gene-Guided chemo trial aims to improve survival in tough breast cancer
NCT ID NCT05693766
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether using gene tests (MammoPrint and BluePrint) to guide treatment can help people with a certain type of advanced breast cancer (HR+, HER2-negative) live longer. 64 participants will receive either chemotherapy (capecitabine) or hormone therapy based on their gene signature. The study focuses on a diverse group to make findings more widely applicable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Capecitabine (chemotherapy) and endocrine therapy
What this could lead to
If successful, this could show that using gene tests to pick treatments improves survival for people with a hard-to-treat type of breast cancer.
What could go wrong
This is a small, early-phase trial (64 people) with no control group, so results may not apply broadly. Chemotherapy has side effects like fatigue and nausea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact
Contact Phone: •••-•••-••••
-
University of Alabama Birmingham
RECRUITINGBirmingham, Alabama, 35249, United States
Contact
Contact
-
Vanderbilt University/Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••